Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026

뉴스 본문을 불러오고 있어요.

Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026 | 웨이프 WAPE

Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 16.2% Weight Loss; Phase 3 Obesity Program On Track For Q3 2026

기사 요약

관련 종목

댓글 —